Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
The pharmacokinetic disposition of meropenem, administered at 500 mg every 8 h, in plasma and cantharidin-induced blister fluid is described. Peak meropenem concentrations in blister fluid lagged behind peak meropenem concentrations in plasma, while a lower elimination rate from blister fluid was also noted. The mean penetration of meropenem into blister fluid was 67%. The pharmacokinetic profile of meropenem in blister fluid supports the utility of this dose in the management of skin and soft tissue infections.
Maglio
Dana
D
Center for Anti-Infective Research and Development, Division of Infectious Diseases, Office for Research, Hartford Hospital, Hartford, Connecticut 06102, USA.
Teng
Renli
R
Thyrum
Per T
PT
Nightingale
Charles H
CH
Nicolau
David P
DP
D000328:Adult; D019540:Area Under Curve; D001768:Blister / Q000378:metabolism*; D002193:Cantharidin / Q000633:toxicity*; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D000077731:Meropenem; D013845:Thienamycins / Q000008:administration & dosage / Q000493:pharmacokinetics*
D013845:Thienamycins; D000077731:Meropenem; D002193:Cantharidin